Malignant catatonia/neuroleptic malignant syndrome or how to change the view on ECT.
B. Plesničar,Metka Faganelj But,B. Zalar
DOI: https://doi.org/10.1097/00124509-200412000-00018
2004-12-01
Journal of Ect
Abstract:To the Editor: We present a patient with 2 outbursts of catatonia that transformed into malignant catatonia/neuroleptic malignant syndrome (NMS) on both occasions. Electroconvulsive therapy (ECT), which would be indicated in this situation, was not performed. A 37-year-old male with an acute psychotic disorder was first admitted to a military psychiatric hospital when he was 20 years old. His medical records remain inaccessible. After the discharge, he continued treatment with fluphenazine decanoate for 6 years when his behavior suddenly became bizarre and negativistic. He was frightened, attacked his mother, and tried to jump through the window under the influence of persecutory delusions. Upon admission to a psychiatric hospital, he exhibited symptoms included mutism, extreme negativism, echopraxia, persecutory delusions and delusions of reference, periods of catatonia excitement, and stupor. Haloperidol, levopromazine, and diazepam were administered for a few days when his body temperature rose up to 39.8(C with no muscle rigidity; liver enzymes, sodium, creatinine phosphokinase and Creactive protein plasma levels were increased and urine retention and bronchopneumonia occurred. Antipsychotics were discontinued and phenobarbitone was given. A week later his medical condition improved, and he started to communicate with no signs of catatonia, although he was still delusional. Haloperidol was administered in low doses and after 4 months, the patient was discharged in remission. He received fluphenazine decanoate and worked as a secretary for the next 12 years when the depot treatment was discontinued. Two weeks later he became severely agitated, was locking himself in his room, and was afraid of relatives. After readmission treatment with olanzapine, lorazepam, diazepam, and haloperidol yielded no response. This catatonic episode was practically identical to the previous one, including the severely deteriorated condition that now required treatment in the intensive care unit. After 14 days of treatment with lorazepam, all his symptoms began to improve. In remission, he was discharged 2 months later on olanzapine. Nosologic confusion regarding catatonia, malignant catatonia, and NMS still exists. NMS is indistinguishable from malignant catatonia. Dehydration and motor signs of catatonia are harbingers of malignant catatonia with antipsychotic drugs. In our case antipsychotics and deterioration of general condition were probably risk factors for turning simple catatonia into malignant catatonia/NMS. Catatonia has a good prognosis with benzodiazepines and with ECT as a first-line treatment. In our patient, benzodiazepines were not sufficiently effective, and ECT treatment was indicated. However, in Slovenia the use of ECT was discouraged and forbidden 13 years ago, mostly because of pressure from the media. No evidence-based data have yet created enough of an incentive for the experts to overcome this narrowmindedness. Hence, for a great number of patients, including our patient, that could benefit from ECT, this form of treatment remains unattainable.